296 related articles for article (PubMed ID: 27956623)
21. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.
Zheng T; Wang J; Zhao Y; Zhang C; Lin M; Wang X; Yu H; Liu L; Feng Z; Hu W
Nat Commun; 2013; 4():2996. PubMed ID: 24356649
[TBL] [Abstract][Full Text] [Related]
22. The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering.
Ottolini D; Calì T; Negro A; Brini M
Hum Mol Genet; 2013 Jun; 22(11):2152-68. PubMed ID: 23418303
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of ENTPD5 inhibits tumor metastasis and growth via regulating the GRP78/p-eIF-2α/CHOP pathway in serous ovarian cancer.
Chen X; Zha Z; Wang Y; Chen Y; Pang M; Huang L; Chen Y
J Ovarian Res; 2022 Jun; 15(1):69. PubMed ID: 35668504
[TBL] [Abstract][Full Text] [Related]
24. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
[TBL] [Abstract][Full Text] [Related]
26. Ets2 anchors the prometastatic function of mutant p53 in osteosarcoma.
Liu DD; Kang Y
Genes Dev; 2017 Sep; 31(18):1823-1824. PubMed ID: 29051386
[TBL] [Abstract][Full Text] [Related]
27. Mutant p53 improves cancer cells' resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6.
Sicari D; Fantuz M; Bellazzo A; Valentino E; Apollonio M; Pontisso I; Di Cristino F; Dal Ferro M; Bicciato S; Del Sal G; Collavin L
Oncogene; 2019 Aug; 38(34):6184-6195. PubMed ID: 31312025
[TBL] [Abstract][Full Text] [Related]
28. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
[TBL] [Abstract][Full Text] [Related]
29. A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.
Koifman G; Shetzer Y; Eizenberger S; Solomon H; Rotkopf R; Molchadsky A; Lonetto G; Goldfinger N; Rotter V
Cancer Res; 2018 Oct; 78(20):5833-5847. PubMed ID: 30154152
[TBL] [Abstract][Full Text] [Related]
30. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
31. Identifying small molecule probes of ENTPD5 through high throughput screening.
Durst MA; Ratia K; Lavie A
PLoS One; 2019; 14(6):e0210305. PubMed ID: 31242188
[TBL] [Abstract][Full Text] [Related]
32. A DDX31/Mutant-p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer.
Daizumoto K; Yoshimaru T; Matsushita Y; Fukawa T; Uehara H; Ono M; Komatsu M; Kanayama HO; Katagiri T
Cancer Res; 2018 May; 78(9):2233-2247. PubMed ID: 29440146
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
34. Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
Ubertini V; Norelli G; D'Arcangelo D; Gurtner A; Cesareo E; Baldari S; Gentileschi MP; Piaggio G; Nisticò P; Soddu S; Facchiano A; Bossi G
Oncogene; 2015 May; 34(19):2493-504. PubMed ID: 24998848
[TBL] [Abstract][Full Text] [Related]
35. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
36. Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP.
Valentino E; Bellazzo A; Di Minin G; Sicari D; Apollonio M; Scognamiglio G; Di Bonito M; Botti G; Del Sal G; Collavin L
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7623-7628. PubMed ID: 28667123
[TBL] [Abstract][Full Text] [Related]
37. Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice.
Lenfert E; Maenz C; Heinlein C; Jannasch K; Schumacher U; Pantel K; Tolstonog GV; Deppert W; Wegwitz F
Int J Cancer; 2015 Mar; 136(6):E521-33. PubMed ID: 25195563
[TBL] [Abstract][Full Text] [Related]
38. Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter.
Vaughan CA; Pearsall I; Singh S; Windle B; Deb SP; Grossman SR; Yeudall WA; Deb S
Oncotarget; 2016 Mar; 7(11):12426-46. PubMed ID: 26820293
[TBL] [Abstract][Full Text] [Related]
39. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
[TBL] [Abstract][Full Text] [Related]
40. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246.
Cooks T; Pateras IS; Jenkins LM; Patel KM; Robles AI; Morris J; Forshew T; Appella E; Gorgoulis VG; Harris CC
Nat Commun; 2018 Feb; 9(1):771. PubMed ID: 29472616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
